Imara M&A

Chronic Myeloid Leukemia A big success story for precision oncology, but needs remain as treatment goals have evolved Prior to imatinib the annual CML mortality rate: <20% 1985 BCR-ABL protein identified Survival Probability 1.0 0.8 0.6 0.4 0.2 0.0 0 1987 HTS yielded the discovery of STI-571 (imatinib) CML 10-Year Survival Rate Over Time TK 2001-day (CML-related deaths) 445 17 Ti 2001-40day (all deaths) 1996-2000 581 178 367 220 415 308 227 220 1983-1990 1982 1 2 3 4 1998 Imatinib FIH study initiated 5 6 7 Years 8 9 92% 83% 43% 35% 8% 10 11 2001 Imatinib approved 10-year survival rate improved from <20% to over >80% 12 13 14 2006 Dasatinib approved CML = Chronic myeloid leukemia. FIH = First-in-human. MMR = Major molecular response. TFR = Treatment-free reemission References: Huang X et al. Cancer. 2012;118:3213-3127. DOI: 10.1002/cncr.26679; Kantarjian et al. Chronic Myeloid Leukemia, In: Harrison's Principles of Internal Medicine. 2014. 2007 Nilotinib approved Estimated Prevalence of CML in the US Over Time Number of CML Patients 200000 180000 160000 140000 120000 100000 80000 60000 40000 20000 Number of patients living with CML has more than doubled since introduction of TKIs 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 Year 2012 Ponatinib and Bosutinib approved 2013 NCCN Update (MMR) 2016 Generic imatinib becomes available 2021 Asciminib 3L approval 2017 Emerging Treatment Goals (MR4.5, TFR) 19

View entire presentation